Background Inaccurate estimates of diabetes-related healthcare costs can undermine the efficiency of resource allocation for diabetes care. The quantification of these costs using claims data may be affected by the method for defining diagnoses. Objectives The aims were to use panel data analysis to estimate diabetes-related healthcare costs and to comparatively evaluate the effects of diagnostic definitions on cost estimates. Research design Monthly panel data analysis of Japanese claims data. Subjects The study included a maximum of 141,673 patients with type 2 diabetes who received treatment between 2005 and 2013. Measures Additional healthcare costs associated with diabetes and diabetes-related complications were estimated for various diagnostic definition methods using fixed-effects panel data regression models.
Introduction
Accurately estimating the healthcare costs associated with diabetes can guide the efficient distribution of resources for diabetes care. The American Diabetes Association estimated the direct medical costs for diabetes in the USA to be approximately US$176 billion in 2012 [1] . In contrast, the estimate for 2007 was much lower, at US$116 billion, indicating an increase of 51.7 % in only 5 years [2] . Diabetes therefore represents a major healthcare issue with considerable macroeconomic impact.
By estimating the costs associated with specific diseases and quantifying the budget impact of various therapies, decision-makers are able to prioritize the distribution of resources toward the treatment and prevention of diseases that require urgent attention [3] . In addition, cost data can also be used directly in cost-effectiveness analyses. The additional healthcare costs due to diabetes and diabetes-related complications may represent potential cost savings that would result from preventing these diseases. In this way, the calculation of these costs can guide the policymaking process for diabetes control measures.
Due to these important policy applications associated with quantifying the economic impact of diabetes, numerous studies from various countries have estimated the additional costs incurred by this disease [4] [5] [6] . Insurance claims databases present a convenient tool for estimating healthcare costs in large sample sizes, but current databases suffer from limitations in the definition and identification of specific disease diagnoses. As each country uses an essentially unique format for insurance claims data, different countries would have different options available for defining diagnoses, such as definitions limited only to the principal diagnosis, those that include other conditions, those that incorporate drug prescription information, and those that incorporate clinical examination results [4, [7] [8] [9] . Because there are numerous possible methods to define diagnoses in claims data, healthcare cost estimates are expected to differ depending on the method used [9] .
If healthcare cost estimates are substantially affected by disease definition, analysts may be inclined to select the method that produces results most favorable to their narrative. This may undermine the efficient distribution of resources based on healthcare cost data, and diminish the social significance of this type of research. This study evaluates the effects of different definitions for diabetes diagnoses on healthcare cost estimates in Japan.
Research Design and Methods

Data Source
The study was conducted using data extracted from the Japan Medical Data Center Claims Database, which is a commercially available database comprising administrative claims data from 3,139,731 insurance enrollees across 52 employee health insurers.
Japan utilizes a universal healthcare system in which all citizens and long-term residents (who reside in Japan for 1 year or more) enroll in regional insurance, employee insurance, or insurance for elderly persons. Under this system, insured individuals are free to seek care at any clinic, hospital, or pharmacy throughout the country. Patients are responsible for copayment when they receive healthcare services and products that are covered under insurance, and the healthcare institutions submit claims to insurers in order to be reimbursed for the remaining amount.
These claims data consist of basic patient characteristics (sex and age), recorded diagnoses, and detailed information on the medical treatment provided to patients. The latter includes inpatient fees, outpatient fees, and prescription drug dispensing fees for services covered by health insurance. However, claims for services covered by nursing care insurance are not included. Each recorded diagnosis is accompanied by a corresponding International Classification of Diseases, 10th Revision (ICD-10) code for identification purposes.
In this study, cost and healthcare utilization data for claims involving inpatient, outpatient, and drug dispensing services were summarized at the per-patient-per-month (PPPM) level. As the data used were insurance claims data, this analysis was conducted from the perspective of public healthcare payers.
Inclusion and Exclusion of Participants
Subjects were included in our analysis if their claims data had at least one recorded diagnosis of type 2 diabetes during the study period from January 2005 to June 2013. However, cases were censored if the subjects had changed insurers (due to changes in employment or other reasons), died, or became 75 years or older during the study period. Subjects who changed insurers during the study period were censored because this study utilized data from employee health insurers, which did not allow the tracking of subjects through changes in insurers. We excluded the following patients from analysis: (1) those who had developed visual impairment before or during the study period (i.e., those with a diagnosis of amaurosis, visual impairment, or total blindness); (2) those who had begun dialysis treatment for non-diabetic nephropathy before the study period; (3) those who had undergone dialysis treatment with a diagnosis of acute renal failure during the study period; (4) those who had a diagnosis of a malignant neoplasm during the study period; (5) those who had undergone surgical procedures for conditions other than those listed in Table 1 during the study period; and (6) those with a recorded diagnosis of type 1 diabetes.
Exclusion criteria 1-3 were employed as this study also aimed to examine the relationship between healthcare costs and the presence and progression of diabetes-related complications. Because patients with late-stage complications (such as those who require dialysis or have visual impairments) would undergo very different treatments from other patients, their inclusion may confound the analysis of the association between costs and disease progression. Furthermore, the healthcare costs for treating malignant neoplasms and conducting surgical procedures unrelated to diabetes would account for a large proportion of overall costs. In order to focus on costs that are more representative of diabetes patients, we excluded the cases described in criteria 4 and 5. We also excluded patients with a recorded diagnosis of type 1 diabetes and those who were under 20 years of age at the start of the study period to restrict the sample to patients with type 2 diabetes (ICD-10 codes E10-E14).
Diagnostic Definitions for Diabetes
Type 2 diabetes was identified using the corresponding ICD-10 codes (E10-E14). To investigate the influence of diagnostic definition method on cost estimates, we analyzed six different methods for defining diagnoses. Healthcare cost estimates were calculated for each of these diagnostic definitions.
There are three possible forms for each diagnosis in Japanese claims data: normal diagnosis, rule-out diagnosis, and principal diagnosis [10, 11] . Under the Japanese health insurance system, healthcare providers are required to justify their use of all medical and surgical services in order to be reimbursed by the insurers. After receiving the submitted claims data, the insurers conduct a review of the reported diagnoses and health services provided. Based on this review, the insurers can deny reimbursements for treatments that are determined to be inappropriate or unnecessary for the reported diagnoses. As a result, healthcare providers in Japan frequently record a suspected disease as a rule-out diagnosis for the purpose of insurance, which allows physicians to conduct tests and other services that they deem necessary in the course of treatment even if the suspected disease is eventually found to be absent in the patient. Next, when providers submit claims for a patient with several different diagnoses, the rules for reimbursement dictate that one of these diagnoses must be designated the principal diagnosis. However, there are no clear criteria on what constitutes a principal diagnosis, and providers are not restricted from designating two or more principal diagnoses in practice. In addition to the recorded diagnoses, previous studies have shown that diabetes can also be indirectly identified by analyzing the use of anti-diabetic medications [7, 9] . As monthly claims data include detailed information on all medical treatments and drugs provided to each patient, analysts are able to determine if anti-diabetic medications were prescribed in any given month. Anti-diabetic medications were identified according to codes (A10C1-A10X9) based on the Anatomical Classification of Pharmaceutical Products, which is developed and maintained by the European Pharmaceutical Market Research Association.
For this analysis, we formulated the following six definitions for diabetes diagnosis: definition 1: record of diabetes excluding those flagged as rule-out diagnoses (exclusion of rule-out diagnoses); definition 2: record of diabetes including those flagged as rule-out diagnoses (inclusion of rule-out diagnoses); definition 3: record of diabetes as the principal diagnosis (principal diagnosis); definition 4: definition 1 with a recorded dispensation of anti-diabetic medication (exclusion of rule-out diagnoses with anti-diabetic medication); definition 5: definition 2 with a recorded dispensation of anti-diabetic medication (inclusion of rule-out diagnoses with anti-diabetic medication); and definition 6: definition 3 with a recorded dispensation of anti-diabetic medication (principal diagnosis with anti-diabetic medication).
For chronic diseases such as diabetes, patients are typically not required to undergo monthly clinical examinations. As a result, many patients only visit their healthcare providers once every few months. This study used a monitoring interval of 3 months, which was based on the American Diabetes Association recommendation of conducting measurements approximately once every 3 months [12] . Under this stipulated monitoring interval, if a patient received treatment in the index month and was subsequently treated again only in the third month, the intermediate 2-month period without examination would still be considered a monitoring period that was part of active treatment. However, if a patient received treatment in the index month but did not undergo examination in the following 3 months, they were considered to have ceased treatment. In these cases, the period between the index month and the subsequent examination were not considered part of active treatment. 
Identification of Diabetes-Related Complications
To estimate the additional healthcare costs according to the type and stage of diabetes-related complications, we identified these factors based on the definitions provided by Kitazato et al.
(an English version of the definitions is provided in Table S1 in the electronic supplementary material) [13] .
Only complications that occurred after the initial diagnosis of diabetes were analyzed. Similar to the monitoring interval for diabetes, we also set 3-month monitoring intervals for retinopathy without surgery, renal proteinuria, renal failure, lesions on extremities without surgery, coronary artery disease without surgery, and stroke without hospitalization.
Statistical Analysis
To provide an overview of the study sample and claims data, we first conducted a descriptive analysis of patient characteristics for each of the diagnostic definition methods. Healthcare costs were aggregated at the PPPM level.
In addition to monthly total healthcare costs, diagnoses, and medical treatment, the claims database allows the examination of patient data prior to occurrence of the target disease. As a result, panel data analysis enables the establishment of baseline healthcare costs for each patient before the target disease occurred, as well as cost estimates from outside the contiguous 3-month monitoring intervals. Our claims data also allow analysts to account for the effects of any reported complication. Therefore, we used fixed-effects panel data regression models to estimate the additional healthcare costs associated with diabetes and diabetes-related complications. Fixed-effects models use within-person variations in the independent variables to explain the within-person variations in the dependent variable. The use of this approach allows us to account for time-invariant unobserved confounders that may potentially bias the cost estimates. The model used in this study can be described using the following equation:
where ''Healthcare Cost i , t '' refers to the healthcare costs for patient ''i'' in month ''t'', ''Diabetes'' indicates whether the patient was under active treatment, ''Complications'' refers to the recorded diagnosis of the complications listed in Table 1 , ''Age'' refers to the patient's age, ''v i '' refers to the time-invariant patient factors (fixed effects), and ''u i,t '' is the error term. To calculate the itemized breakdown of the healthcare costs according to whether or not a patient had a target disease, we estimated the marginal effects for diabetes and each diabetes-related complication.
Reported costs were converted to US dollars using the purchasing power parity index of 2014 (US$1 = ¥104). All analyses were performed using Stata release 13.1 (StataCorp, College Station, TX, USA). Table 1 
Results
approximately 28.9-43.5 % of the patients, while dependents accounted for 24.4-30.9 %. The average age of the study sample was approximately 50 years. While the frequency of diabetes-related complications also varied according to the diagnostic definition method, the incidences of retinopathy without surgery, renal proteinuria, ischemic heart disease (IHD) without surgery, and cerebrovascular disease (CVD) without hospitalization were consistently high. The incidences of retinopathy without surgery and renal proteinuria in the definition 1 group (exclusion of rule-out diagnoses) were 12.0 and 7.7 %, respectively; these incidences were doubled in the definition 3 group (principal diagnosis) and the groups that incorporated anti-diabetic medications (definitions 4-6). Table 2 shows the estimates of the fixed-effects models for each diagnostic definition method. These estimates represent the quantitative changes to the patient-level healthcare costs PPPM in the months where diabetes or diabetes-related complications occurred. Although the individual P values are not presented in the table, all independent variables were significantly associated (P \ 0.001) with increases in healthcare costs. The additional costs PPPM associated with diabetes varied among the different definitions, and ranged from US$180 [95 % confidence interval (CI) 178-181] for definition 3 (principal diagnosis) to US$223 (95 % CI 221-224) for definition 2 (inclusion of rule-out diagnoses). For definition 1 (exclusion of rule-out diagnoses), the diabetes-related complications associated with higher additional healthcare costs PPPM were IHD with surgery (US$13,595; 95 % CI 13,568-13,622), neuropathy/extremity disease (NED) with surgery (US$4594; 95 % CI 3979-5208), and diabetic nephropathy with dialysis (US$3689; 95 % CI 3667-3711). Table 3 summarizes the marginal effects of the additional healthcare costs using definition 1 (exclusion of rule- 
Values are presented as coefficients (95 % confidence intervals) that indicate the additional healthcare costs PPPM in US$ (2014) CVD cerebrovascular disease, IHD ischemic heart disease, NED neuropathy/extremity disease, PPPM 
Discussion
In this study, we used information available in Japanese insurance claims data to examine the impact of various definitions for diagnosing diabetes on healthcare cost estimates. Our investigation revealed that the number of subjects for analysis and their healthcare cost estimates varied among the different definition methods. This study is characterized by the use of monthly panel data sets derived from claims data, which differs from traditional healthcare cost analyses that use cross-sectional data. To the best of our knowledge, this is the first study to use monthly panel data sets to investigate healthcare costs, and this method allows analysts to account for the inherent variations in individual patient characteristics and complications.
A major methodological feature of this study is the inclusion of information that precedes the initial diagnosis of diabetes, as well as during months without diabetes treatments. The majority of existing cross-sectional studies that utilized regression-based analyses have done so to estimate the differences in healthcare costs between patients with and without a specific disease [14] [15] [16] [17] [18] [19] [20] [21] [22] . However, that analytical method may not be able to adequately account for the inherent variations among patients. This limitation is particularly prominent in studies that use administrative claims data, which are limited in the variety and depth of information that would facilitate the adjustment of patient-level variations. To overcome this limitation, claims data may be converted into panel data sets at the patient and monthly levels, which analysts can use to investigate the differences in healthcare costs between months with and without examinations. Using this approach, it may be possible to obtain cost estimates that sufficiently account for inter-patient variations. Also, analysts are unable to distinguish between pre-existing conditions and medical complications that occur after the target disease when using cross-sectional data. Similarly, the conversion of claims data into panel data sets enables evaluations across time points, and allows the identification of complications that occur only after the target disease has been diagnosed [7] . While previous studies have examined complications using panel data sets at the patient and yearly levels [7, 8, [23] [24] [25] , the use of monthly claims data would provide greater accuracy in determining the period of disease development.
We believe this to be the first comprehensive examination of the variations in healthcare costs among different diagnostic definitions for diabetes using claims data. In Japanese claims data, rule-out diagnoses are included when The ''Without disease'' column presents the mean costs PPPM under the assumption that all patients are negative for the target disease; the ''With disease'' column presents the mean costs PPPM under the assumption that all patients are positive for the target disease CI confidence interval, CVD cerebrovascular disease, IHD ischemic heart disease, ME marginal effect, NED neuropathy/extremity disease, PPPM per-patient-per-month physicians order tests or provide treatment for a suspected (unconfirmed) disease, and their inclusion allows providers to be reimbursed for these services. As reimbursement systems vary widely among countries, there may be systems outside of Japan that only include principal diagnoses or do not take into account the various services provided for each recorded diagnosis. Therefore, it should be noted that the use of rule-out diagnoses in claims database research may not be applicable to all countries. Oglesby et al. previously compared the medical costs between patients who had received a diagnosis of diabetes but were not prescribed insulin and patients who had received both a diagnosis of diabetes and an insulin prescription [9] . Their results clearly demonstrated that the costs of insulin users were higher than those of non-users, which was congruent with expectations as the former would, at the minimum, incur additional drug costs. However, that study did not address the influence of a principal diagnosis designation on healthcare cost estimates, or the effects of incorporating the use of other anti-diabetic medications to identify subjects. In our analysis, definition 2 (inclusion of rule-out diagnoses) identified the highest number of subject patients, followed by definition 1 (exclusion of rule-out diagnoses), definition 5 (inclusion of rule-out diagnoses with anti-diabetic medication), definition 4 (exclusion of rule-out diagnoses with anti-diabetic medication), definition 3 (principal diagnosis), and definition 6 (principal diagnosis with anti-diabetic medication). The number of patients identified using the principal diagnosis (definition 3) was similar to the number of patients identified using the definitions that incorporated anti-diabetic medications (definitions [4] [5] [6] . This suggests drug utilization information may contribute to the identification of patients with diabetes as a major condition even if there is no record of diabetes as the principal diagnosis. There was a difference of approximately 46,000 people between the definitions that incorporated anti-diabetic medications and those that did not. If we were to restrict our analysis to patients who were prescribed anti-diabetic medications, there is a high possibility that we would overlook patients with milder forms of diabetes that are being managed with appropriate diet and exercise, which is not reflected in drug prescription data. The highest additional healthcare costs associated with diabetes were observed in patients identified using definition 2. This was followed by definition 5, definition 4, definition 6, definition 1, and definition 3. It is possible that some rule-out diagnoses are given to support the legitimacy of insurance claims for treatments that the attending physician wishes to provide. For example, a physician may give a ''suspected diabetes'' diagnosis to a patient who has been admitted for a condition unrelated to diabetes in order to administer an hemoglobin A1c (HbA1c) test. A possible reason for patients with rule-out diagnoses having the highest additional healthcare costs may be that a large proportion of these patients also suffer from a number of other conditions, and their associated costs accumulate on top of the diabetes-related costs. On the other hand, there was only a PPPM cost difference of US$14 between patients in the definition 1 and definition 4 groups, and this difference may simply represent the additional costs for medication. We were unable to clarify the reason for the low additional healthcare costs incurred by the principal diagnosis group. However, the designation of a condition as the principal diagnosis is based on the subjective assessment of the attending physician, and the lack of standardized assessment criteria means that actual diabetic patients may not always be identified as such. From our analysis of patient numbers and additional healthcare costs, the use of definition 1 (exclusion of rule-out diagnoses) appears to be suitable for identifying type 2 diabetes patients through Japanese claims data.
The additional healthcare costs PPPM associated with diabetes (defined using definition 1) were estimated to be US$208 (95 % CI 207-209). The mean additional costs for months in which the patients underwent clinical examinations for diabetes were five times that of months without examinations. While numerous studies have estimated the healthcare costs associated with diabetes and diabetes-related complications, few have calculated the incremental ratios. In an analysis of claims data from 2005, Durden et al. used propensity score matching and a generalized linear model to compare diabetic patients and non-diabetic patients; they reported that the healthcare costs of diabetic patients were 2.36 times higher than those of non-diabetic patients [21] . A possible reason for the large disparity between the results of this study and that of Durden et al. is that the latter had conducted an analysis over a period of only 1 year, whereas our study employed a monthly panel data analysis with a mean follow-up period of 51.4 months per patient. In addition, we also included the mean costs associated with diabetes-related complications. Lee et al. conducted an analysis of claims data from 1999 to 2004 to examine diabetes-related complications [19] . In that study, they estimated that the additional healthcare costs for patients with diabetic retinopathy were 1.75 times that of patients without this complication. In an investigation of pooled data from 2004 and 2006, Fu et al. reported that diabetic patients with macrovascular comorbid conditions had healthcare costs that were approximately twice that of patients without these conditions [20] . As indicated in Table 3 , our study showed that the additional costs associated with diabetic retinopathy and IHD without surgery were approximately twice that of patients without these complications, which corroborates the findings of previous studies.
This study has limitations that are characteristic to the use of claims data to calculate healthcare costs in diabetic patients. First, as we had used claims data as the sole data source, we were unable to analyze the results of laboratory tests. For example, we were unable to adjust for disease severity using the HbA1c test. However, Pagano et al. reported that HbA1c results do not have a large effect on healthcare costs, indicating that the lack of this data may not be a critical issue for our study [18] . Second, our study was conducted on working individuals enrolled in employee health insurance, thereby leading to an underrepresentation of elderly patients in our sample. The proportion of patients aged 65 years or older in our study sample was approximately 6.2 %. According to the National Health and Nutrition Survey conducted by Japan's Health Service Bureau [26] , the prevalence of diabetesrelated complications among diabetic patients in 2007 was as follows: 10.6 % for retinopathy, 11.1 % for nephropathy, and 11.8 % for neuropathy. In contrast, the corresponding figures in our study sample in the same month and year as the national survey were 7.2 % for retinopathy, 8.9 % for nephropathy, and 4.4 % for neuropathy. These differences in prevalence may be explained in part by the differences in age distribution between our study sample and the overall population. Elderly patients are more likely to have diabetes and multiple complications, and may therefore receive treatment at hospitals for various different diseases. In addition, mortality can incur substantially higher healthcare costs, and the higher mortality rates associated with increasing age suggest that our findings may not be applicable to a population with more elderly patients. Third, claims data are not medical records, and the accuracy of the recorded diagnoses is uncertain. Hospitals in Japan are not reimbursed for healthcare services if there are no corresponding diagnoses to justify their use, and it is therefore unlikely for the claims data of diabetic patients to lack a recorded diagnosis of diabetes. In contrast, it is possible that the claims data of some non-diabetic patients may include a recorded diagnosis of diabetes. The inclusion of a substantial number of the latter cases may result in an underestimation of healthcare costs. Therefore, the coding accuracy of the data may trend toward higher sensitivity but lower specificity. In addition, reimbursements are contingent on the inclusion of recorded diagnoses in claims data, and hospitals are therefore likely to ensure that there are no missing data in these records.
Conclusion
In this study, healthcare cost estimates for diabetes were found to be sensitive to different diagnostic definitions. Investigating the appropriate definitions of these factors can further advance healthcare cost research and its applications in healthcare policies. However, optimal definitions may vary according to the target disease and subject population. Analysts can calculate and compare healthcare cost estimates for various diseases based on the methodological approach established in this study, and determine the optimal diagnostic definition for accurately identifying each specific disease using claims data.
